title: Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
abstract: BACKGROUND
  Although case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear.
  
  
  OBJECTIVE
  Evaluate previously identified SNPs for association with prostate cancer and accuracy in predicting prostate cancer in a large prospective population-based cohort of unscreened men.
  
  
  METHODS
  This study used a nested case-control design based on the Malmö Diet and Cancer cohort with 943 men diagnosed with prostate cancer and 2829 matched controls. Blood samples were collected between 1991 and 1996, and follow-up lasted through 2005.
  
  
  METHODS
  We genotyped 50 SNPs, analyzed prostate-specific antigen (PSA) in blood from baseline, and tested for association with prostate cancer using the Cochran-Mantel-Haenszel test. We further developed a predictive model using SNPs nominally significant in univariate analysis and determined its accuracy to predict prostate cancer.
  
  
  CONCLUSIONS
  Eighteen SNPs at 10 independent loci were associated with prostate cancer. Four independent SNPs at four independent loci remained significant after multiple test correction (p<0.001). Seven SNPs at five independent loci were associated with advanced prostate cancer defined as clinical stage≥T3 or evidence of metastasis at diagnosis. Four independent SNPs were associated with advanced or aggressive cancer defined as stage≥T3, metastasis, Gleason score≥8, or World Health Organization grade 3 at diagnosis. Prostate cancer risk prediction with SNPs alone was less accurate than with PSA at baseline (area under the curve of 0.57 vs 0.79), with no benefit from combining SNPs with PSA. This study is limited by our reliance on clinical diagnosis of prostate cancer; there are likely undiagnosed cases among our control group.
  
  
  CONCLUSIONS
  Only a few previously reported SNPs were associated with prostate cancer risk in the large prospective Diet and Cancer cohort in Malmö, Sweden. SNPs were less useful in predicting prostate cancer risk than PSA at baseline.
authors.affiliation: Program in Cancer Biology and Genetics, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. kleinr@mskcc.org
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Klein
authors.forename: Christer
authors.initials: C
authors.lastname: Hallden
authors.forename: Amit
authors.initials: A
authors.lastname: Gupta
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Savage
authors.forename: Anders
authors.initials: A
authors.lastname: Dahlin
authors.forename: Anders
authors.initials: A
authors.lastname: Bjartell
authors.forename: Jonas
authors.initials: J
authors.lastname: Manjer
authors.forename: Peter T
authors.initials: PT
authors.lastname: Scardino
authors.forename: David
authors.initials: D
authors.lastname: Ulmert
authors.forename: Peter
authors.initials: P
authors.lastname: Wallström
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Vickers
authors.forename: Hans
authors.initials: H
authors.lastname: Lilja
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D016022:Case-Control Studies; D055088:Early Detection of Cancer; D056426:Genetic Loci; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000235:genetics*; D012307:Risk Factors; D013548:Sweden
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
references.citation: Nat Genet. 2010 Jul;42(7):570-5
references.pmid: 20562874
references.citation: Prostate. 2010 Feb 15;70(3):270-5
references.pmid: 19902474
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4255-67
references.pmid: 20585100
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1285-9
references.pmid: 19318432
references.citation: Clin Cancer Res. 2009 May 1;15(9):3231-7
references.pmid: 19366831
references.citation: BMC Genet. 2007 Aug 28;8:58
references.pmid: 17725844
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1142-7
references.pmid: 16775173
references.citation: Clin Cancer Res. 2010 Sep 1;16(17):4374-81
references.pmid: 20736330
references.citation: Nat Genet. 2009 Feb;41(2):221-7
references.pmid: 19151717
references.citation: Cancer Prev Res (Phila). 2010 May;3(5):611-9
references.pmid: 20424135
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2035-42
references.pmid: 20696662
references.citation: J Nutr. 2009 May;139(5):993-1001
references.pmid: 19321582
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1203-13
references.pmid: 18483343
references.citation: Nat Genet. 2008 Oct;40(10):1153-5
references.pmid: 18758462
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1659-62
references.pmid: 19423541
references.citation: N Engl J Med. 2004 May 27;350(22):2239-46
references.pmid: 15163773
references.citation: Cancer. 1996 Jan 1;77(1):138-43
references.pmid: 8630920
references.citation: J Natl Cancer Inst. 2007 Oct 17;99(20):1525-33
references.pmid: 17925536
references.citation: N Engl J Med. 2008 Feb 28;358(9):910-9
references.pmid: 18199855
references.citation: Sci Transl Med. 2010 Dec 15;2(62):62ra92
references.pmid: 21160077
references.citation: BMJ. 2010 Sep 14;341:c4521
references.pmid: 20843935
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1083-8
references.pmid: 20332264
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):255-61
references.pmid: 21148123
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2869-76
references.pmid: 20978177
references.citation: Int J Cancer. 2012 Jan 1;130(1):129-37
references.pmid: 21328341
references.citation: Clin Cancer Res. 2009 Mar 1;15(5):1787-93
references.pmid: 19223501
references.citation: J Natl Cancer Inst. 2009 Oct 7;101(19):1330-6
references.pmid: 19726753
references.citation: Cancer. 2011 Mar 15;117(6):1210-9
references.pmid: 20960520
references.citation: Eur J Cancer Prev. 2001 Dec;10(6):489-99
references.pmid: 11916347
references.citation: Eur Urol. 2011 Jul;60(1):21-8
references.pmid: 21295399